Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 6/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CCR5 | P51681 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | CCR3 | P51677 | 1/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13929302 | 0.85 | TSHR (0.52) | SIGMAR1GAATSHRTP53 | |
| SCHEMBL13929300 | 0.82 | SIGMAR1 (0.44) | SIGMAR1TSHRCCR5PKMCCR3 | |
| SCHEMBL4220531 | 0.81 | SIGMAR1 (0.54) | SIGMAR1TSHRPKMCCR3OPRM1 | |
| SCHEMBL13929262 | 0.78 | SIGMAR1 (0.48) | SIGMAR1TSHRALDH1A1CCR5PKM | |
| SCHEMBL13929298 | 0.78 | MAPT (0.44) | SIGMAR1USP2GAAALDH1A1 | |
| SCHEMBL13929291 | 0.77 | SIGMAR1 (0.46) | SIGMAR1TSHRCCR5PKMCCR3 | |
| SCHEMBL13929263 | 0.76 | PKM (0.54) | SIGMAR1TSHRPKMCCR3OPRM1 | |
| SCHEMBL13929229 | 0.76 | OPRM1 (0.50) | SIGMAR1TSHRPKMOPRM1 | |
| SCHEMBL13951541 | 0.75 | TSHR (0.47) | SIGMAR1GAATSHRALDH1A1TP53 | |
| SCHEMBL13929239 | 0.74 | PKM (0.52) | SIGMAR1TSHRPKMCCR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090054451-A1 | Use of Piperidine Derivatives as Agonists of Chemokine Receptor Activity | EUROSCREEN S.A. (BE) | 2009-02-26 | — | — | US | disclosed |
| US-20090054451-A1 | Use of Piperidine Derivatives as Agonists of Chemokine Receptor Activity | EUROSCREEN S.A. (BE) | 2009-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054451-A1 | Use of Piperidine Derivatives as Agonists of Chemokine Receptor Activity | ACKR3, CCR5, CCR7 | SIGMAR1 129/4885USP2 3855/4885GAA 4689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.